We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
A sports platform where the user can invest, trade and support their favourites clubs and athletes. The Globatalent platform gives everyone the chance to invest in top prospect sports athletes and organisations from around the globe. Globatalent’s potential market of sports fans is vast, covering 97% of the world’s population. The Globatalent platform has already been built, tested, launched and is generating revenue since Feb 2019. Currently, the platform is managing a total of £1.2m in assets. With the proceeds, they are going to spend on marketing, technology, increase the customer base and cover the day-to-day operational costs.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £420,931
The Wave in Bristol aim to build an in-land surfing lake. It is designed to produce consistent perfect waves without having to wait. If you're not into surfing then there will be a multitude of other activities to get involved in. 
days to go: Expired investment: £20,000
ITIG have developed software to aid in understanding the investment process, as well as reducing the associated costs of investing. Using their licensed methodologies, retail and institutional investors will see return funds which are more predictable when investing in Exchange Traded Funds (ETFs), resulting in highly diverse and low-cost investment portfolio.
days to go: Expired investment: £67,000
Those who work in services, such as the Armed Forces, can find it difficult to access financial products due to their anomalous credit histories compared to non-services personnel. TSFL aims to address this with their advanced risk-modelling platform for underwriters. This will allow tailored insurance, consumer credit and eventually home lending to be sold through TSFL.
days to go: Expired investment: £1,431,885
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button. 
days to go: Expired investment: £1,406,667
An IT recruitment and training site launched to meet the demands of enterprises that require highly skilled tech professionals. 365 Talent Portal offers companies to hire IT consultants at a lower price compared to traditional recruitment hubs. The company also allows IT professionals registered on the site to access training and certification programmes that will expand their current skillset and become more marketable to potential employers. 365 Talent Portal is raising funds to produce more prominent marketing campaigns and establish their brand in major markets such as the USA. In addition to this, the company will be using AI more heavily and develop a more automated approach on their platform for their customers.
days to go: Expired investment: £156,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph